Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,707 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Enrollment posture brief
Registry condition breast-cancer
OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 9 of 26
FES BPET-DBT in Newly Diagnosed Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT05659797
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
NCT05524584
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Dana-Farber Cancer Institute
NCT06488378
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Baylor Research Institute
NCT04265872
Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
UNC Lineberger Comprehensive Cancer Center
NCT05754749
Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction
University of Florida
NCT06461650
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
University of Colorado, Denver
NCT06430541
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Yale University
NCT05989347
Dissemination of BREASTChoice AIM1-B
UNC Lineberger Comprehensive Cancer Center
NCT07396766
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
Medical College of Wisconsin
NCT06106477
SABER Study for Selected Early Stage Breast Cancer
University of Miami
NCT04360330
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
BriaCell Therapeutics Corporation
NCT06471673
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
H. Lee Moffitt Cancer Center and Research Institute
NCT06435351
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
Rutgers, The State University of New Jersey
NCT05736367
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Mridula George, MD
NCT06139107
NearWave Optical Molecular Monitoring
Indiana University
NCT06744465
Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT07023887
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
University of Wisconsin, Madison
NCT04573231
Brodalumab in the Treatment of Immune-Related Adverse Events
Brian Henick, MD
NCT06673329
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Washington University School of Medicine
NCT06904365
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
University of Alabama at Birmingham
NCT03321045
Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
Innoblative Designs
NCT07206121
Biomarkers to Detect Endocrine Therapy Resistance
University of Wisconsin, Madison
NCT06067503
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT00579514
Clinical Significance of Germline BRCA Mutations
Memorial Sloan Kettering Cancer Center
NCT00579488
Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2
The University of Texas Health Science Center, Houston
NCT06082882
Increasing Screening for Cancer Using EHR-Nudges Replication
Abramson Cancer Center at Penn Medicine
NCT06995703
Collection of Tissue, Blood, and Cells to Be Used For Studying the Causes, Prevention, Diagnosis, and Treatment of Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT00588029
PALbociclib CoLlaborative Adjuvant Study
Alliance Foundation Trials
NCT02513394
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company
NCT03155997
The Breast Program - Translational Cancer Resource
Abramson Cancer Center at Penn Medicine
NCT02798341
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
NSABP Foundation
NCT00382070
Breast Cancer Index (BCI) Registry
Biotheranostics
NCT04875351
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
SWOG Cancer Research Network
NCT00070564
Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT06019988
The Engaging Primary Care in Cancer Survivorship (EPICS) Study
Kaiser Permanente
NCT04745754
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
Radiation Therapy Oncology Group
NCT01349322
MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study
Memorial Sloan Kettering Cancer Center
NCT02301767
The OPBC-07/microNAC Study
University Hospital, Basel, Switzerland
NCT06529302
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
SWOG Cancer Research Network
NCT01674140
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
AstraZeneca
NCT06112379
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
AstraZeneca
NCT02032823
Study of Radiation Exposure and Bilateral Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT00903591
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
Wendie Berg
NCT04085510
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
Klus Pharma
NCT04152499
The Young Women's Breast Cancer Study
Dana-Farber Cancer Institute
NCT01468246
Genomic Structural Variation in Cancer Susceptibility
Memorial Sloan Kettering Cancer Center
NCT00996710
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Merck Sharp & Dohme
NCT03725059
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Abramson Cancer Center at Penn Medicine
NCT02603341
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Hoffmann-La Roche
NCT04873362
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Cancer page
1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 423 Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.